DelveInsight launched a new report on Multiple Myeloma Epidemiology Forecast, 2030.
Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. The immune system is made up of several types of cells that work together to fight infections and other diseases. Lymphocytes (lymph cells) are one of the main types of white blood cells in the immune system and include T cells and B cells. Lymphocytes are in many areas of the body, such as lymph nodes, the bone marrow, the intestines, and the bloodstream.
DelveInsight’s ‘Multiple Myeloma Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Multiple Myeloma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the key highlights from the Multiple Myeloma Epidemiology Report:
In the year 2020, the total incident case of Multiple Myeloma was 91,693 cases in the 7MM and the United States, in 2020, accounted for 32,270 cases (the highest number) which might increase in the forecast period.
In the 7MM, the total gender-specific cases of Multiple Myeloma were 43,910 cases for males and 36,805 cases for females in the year 2020
According to DelveInsight’s analysis, in the 7MM, China reported the second-highest incident cases of Multiple myeloma, i.e., 21,116 which accounted for nearly 23% of the total 7MM cases, in the year 2020.
Visit for more @ Multiple Myeloma Epidemiology Insights
Scope of the Multiple Myeloma Epidemiology report:
The Multiple Myeloma report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
The Multiple Myeloma Epidemiology Report and Model provide an overview of the risk factors and global trends of Multiple Myeloma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight into the historical and forecasted patient pool of Multiple Myeloma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps to recognize the growth opportunities in the 7MM concerning the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Multiple Myeloma
The report provides the segmentation of the Multiple Myeloma epidemiology
Table of Contents:
1. Key Insights
2. Executive Summary of Multiple Myeloma
3. Multiple Myeloma Epidemiology Overview at a Glance
4. Multiple Myeloma: Disease Background and Overview
5. Epidemiology and Patient Population
6. Case Reports
7. Country Wise-Epidemiology of Multiple Myeloma
9. DelveInsight Capabilities
11. About DelveInsight
DelveInsight’s ‘Multiple Myeloma (MM)-Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
“Multiple Myeloma Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Multiple Myeloma market. A detailed picture of the Multiple Myeloma pipeline landscape is provided, which includes the disease overview and Multiple Myeloma treatment guidelines.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States